COVID-19 preclinical drug development database

Preclinical assessment and metabolic activation of the phosphoramidated nucleotide NUC-7738 for repurposing as an anti-SARS-Cov-2 drug.

University of St Andrews

Added 15/05/2020 | Updated 04/10/2021

Back

Project Details

Type of project

  • Tier 1: repurposing existing medicines
  • Tier 2: testing existing molecules

Therapeutic target

  • Preventing virus replication in early disease

Type of supporting technology

Phase of project

  • PK/PD testing and toxicology

Modality (if can be disclosed)*

  • Small molecule
  • ProTide

Molecular/cellular target (if known or can be disclosed)*

Partner institutions/organisations

  • NuCana plc

Key contact

Name: Clarissa Czekster

Email Address: cmc27@st-andrews.ac.uk

Phone Number:

Key Collaborators:

Anticipated timeframe of future outputs

1-3 months

This research project is looking for the following:

Collaborations

Further Details

Abstract or additional information (if available)*

Published outputs (if available)*

Relevant weblinks